Effect of Canagliflozin on sympathetic activity and coronary plaque in DM patients with ACS

Effect of Canagliflozin on sympathetic activity and coronary plaque in DM patients with ACS - Effect of Canagliflozin on sympathetic activity and coronary plaque in DM patients with ACS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025749

Enrollment

Registered

2017-01-23

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DM Patients with ACS

Interventions

Canagliflozin 100mg/day, 36 weeks standard therapy, 36 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. >=20 years old 2.Type 2 DM(>=HbA1c6.5%) with ACS 3.PCI would be required 4.Patients giving written concent by their own volition after being provided sufficient explanation for participation in this clinical trial

Exclusion criteria

Exclusion criteria: 1. Patients receiving insulin injection for DM treatment 2.Severe heart failure 3.Advenced CKD(<eGFR30ml/min or HD) 4.Contraindication of Canagliflozin 5.patinets who are ineligible in the opinion of the investigator

Design outcomes

Primary

Measure	Time frame
NTproBNP Sympathetic activity	—

Countries

Japan

Contacts

Public ContactTadateru Takayama

Nihon University Itabashi Hospital Department of Cardiology

takayama.tadateru@nihon-u.ac.jp03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026